

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/281,430
Filing Date	March 30, 1999
First Named Inventor	INDU PARIKH
Group Art Unit	1615
Examiner Name	Tedd Ware Carlos A. [Signature]
Attorney Docket Number	402076-SKYE PHARMA

RECEIVED
APR 23 2003
TECH CENTER 1600/2900

Sheet 1 of 13

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date if Appropriate
		Application or Patent Number	Kind Code			
CA	A 1	2803582		Cherney	8/20/1957	
	A 2	3137631		Soloway	6/16/1964	
	A 3	3594476		Merrill	7/20/1971	
	A 4	3715432		Merrill	2/6/1973	
	A 5	3755557		Jacobs	8/28/1973	
	A 6	3937668		Zolle	2/10/1976	
	A 7	3960757		Morishita et al.	6/1/1976	
	A 8	4053585		Allison et al.	10/11/1977	
	A 9	4056635		Glen et al.	11/1/1977	
	A 10	4073943		Wretlind et al.	2/14/1978	
	A 11	4078052		Papahadjopoulos	3/7/1978	
	A 12	4089801		Schneider	5/16/1978	
	A 13	4102806		Kondo et al.	7/25/1978	
	A 14	4107288		Oppenheim et al.	8/15/1978	
	A 15	4133874		Miller et al.	1/9/1979	
	A 16	4145410		Sears	3/20/1979	
	A 17	4147767		Yapel, Jr.	4/3/1979	
	A 18	4168308		Wretlind et al.	9/18/1979	
	A 19	4219548		Reller	8/26/1980	
	A 20	4235871		Papahadjopoulos et al.	11/25/1980	
	A 21	4241046		Papahadjopoulos et al.	12/23/1980	
	A 22	4271196		Schmidt	6/2/1981	
	A 23	4298594		Sears et al.	11/3/1981	
	A 24	4302459		Steck et al.	11/24/1981	
	A 25	4308166		Marchetti et al.	12/29/1981	
	A 26	4309421		Ghyczy et al.	1/5/1982	
	A 27	4316884		Alam et al.	2/23/1982	
	A 28	4320121		Sears	3/16/1982	
	A 29	4328222		Schmidt	5/4/1982	
	A 30	4329332		Couvreux et al.	5/11/1982	
	A 31	4331654		Morris	5/25/1982	
	A 32	4332795		Ghyczy et al.	6/1/1982	
	A 33	4332796		Los	6/1/1982	
	A 34	4340594		Mizushima et al.	7/20/1982	
	A 35	4345588		Widder et al.	8/24/1982	
	A 36	4351831		Growdon et al.	9/28/1982	
	A 37	4356167		Kelly	10/26/1982	

Examiner Signature	[Signature]	Date Considered	5/9/05
--------------------	-------------	-----------------	--------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- * An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 13

Complete if Known

Application Number 09/281,430
Filing Date March 30, 1999
First Named Inventor INDU PARIKH
Group Art Unit 1615
Examiner Name Todd Ware
Attorney Docket Number 402076 SKYEPHARMA

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
	A 38	4369182		Ghyczy et al.	1/18/1983	
	A 39	4371516		Gregory et al.	2/1/1983	
	A 40	4378354		Ghyczy et al.	3/29/1983	
	A 41	4394372		Taylor	7/19/1983	
	A 42	4397846		Weiner et al.	8/9/1983	
	A 43	4411894		Schrank et al.	10/25/1983	
	A 44	4411933		Samejima et al.	10/25/1983	
	A 45	4421747		Ghyczy et al.	12/20/1983	
	A 46	4427649		Dingle et al.	1/24/1984	
	A 47	4432975		Libby	2/21/1984	
	A 48	4448765		Ash et al.	5/15/1984	
	A 49	4452817		Imperial Chemical Industrial	6/5/1984	
	A 50	4483847		Augart	11/20/1984	
	A 51	4485054		Mezei et al.	11/27/1984	
	A 52	4492720		Mosier	1/8/1985	
	A 53	4515736		Deamer	5/7/1985	
	A 54	4522803		Lenk et al.	6/11/1985	
	A 55	4610868		Fountain et al.	9/9/1986	
	A 56	4613505		Mizushima et al.	9/23/1986	
	A 57	4622219		Haynes	11/11/1986	
	A 58	4629626		Miyata et al.	12/16/1986	
	A 59	4675236		Ohkawara et al.	6/23/1987	
	A 60	4687762		Fukushima et al.	8/18/1987	
	A 61	4711902		Serno	12/8/1987	
	A 62	4719239		Muller et al.	1/12/1988	
	A 63	4725422		Miyabayashi et al.	2/16/1988	
	A 64	4756910		Yagi et al.	7/12/1988	
	A 65	4758598		Gregory	7/19/1988	
	A 66	4762720		Jizomoto	8/9/1988	
	A 67	4766046		Abra et al.	8/23/1988	
	A 68	4776991		Farmer et al.	10/11/1988	
	A 69	4798846		Imperial Chemical Industrial	1/17/1989	
	A 70	4798860		Parr	1/17/1989	
	A 71	4800079		Boyer	1/24/1989	

Examiner Signature

Date Considered

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 13

Complete if Known

Application Number 09/281,430
Filing Date March 30, 1999
First Named Inventor INDU PARIKH
Group Art Unit 1615
Examiner Name Todd Ware
Attorney Docket Number 402076 SKYEPHARM

RECEIVED

APR 23 2003

TECH CENTER

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
OK	A 7 2	4801455		List et al.	1/31/1989	
	A 7 3	4803070		Cantrell et al.	2/7/1989	
	A 7 4	4806350		Gerber	2/21/1989	
	A 7 5	4806352		Cantrell	2/21/1989	
	A 7 6	4826687		Nerome et al.	5/2/1989	
	A 7 7	4839111		Huang	6/13/1989	
	A 7 8	4880634		Speiser	11/14/1989	
	A 7 9	4895726		Curtet et al.	1/23/1990	
	A 8 0	4961890		Boyer	10/9/1990	
	A 8 1	4963367		Ecanow	10/16/1990	
	A 8 2	4973465		Baurain et al.	11/27/1990	
	A 8 3	4990337		Kurihara et al.	2/5/1991	
	A 8 4	5030453		Lenk et al.	7/9/1991	
	A 8 5	5091187		Haynes	2/25/1992	
	A 8 6	5091188		Haynes	2/25/1992	
	A 8 7	5098606		Nakajima et al.	3/24/1992	
	A 8 8	5100591		Leclef et al.	3/31/1992	
	A 8 9	5128147		Leveen et al.	7/7/1992	
	A 9 0	5145684		Liversidge et al.	9/8/1992	
	A 9 1	5152923		Weder et al.	10/6/1992	
	A 9 2	5164380		Carli et al.	11/17/1992	
	A 9 3	5167950		Lins	12/1/1992	
	A 9 4	5169847		Nagy nee Kriesfalussy et al.	12/8/1992	
	A 9 5	5178878		Wehling et al.	1/12/1992	
	A 9 6	5179079		Hansen et al.	1/12/1993	
	A 9 7	5217707		Szabo et al.	6/8/1993	
	A 9 8	5246707		Haynes	9/21/1993	
	A 9 9	5256422		Micro Vesicular Sys., Inc.	10/26/1993	
	A 1 0 0	5269979		Fountain	12/14/1993	
	A 1 0 1	5272137		Blasé et al.	12/21/1993	
	A 1 0 2	5298262		Na et al.	3/29/1994	
	A 1 0 3	5302401		Liversidge et al.	4/12/1994	
	A 1 0 4	5304564		Tsuboi et al.	4/19/1994	
	A 1 0 5	5314915		Rencher	5/24/1994	
	A 1 0 6	5326552		Na et al.	7/5/1994	
	A 1 0 7	5336507		Na et al.	8/9/1994	
	A 1 0 8	5338761		Nakajima et al.	8/16/1994	
	A 1 0 9	5340564		Illig et al.	8/23/1994	
	A 1 1 0	5346702		Na et al.	9/13/1994	

Examiner Signature

Date Considered

5/4/05

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

13

Complete if Known

Application Number 09/281,430
Filing Date March 30, 1999
First Named Inventor INDU PARIKH
Group Art Unit 1615
Examiner Name Todd Ware
Attorney Docket Number 402076 SKYEPHARM

RECEIVED

APR 23 2003

RECEIVED 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
CA	A 1 1 1	5352459		Hollister et al.	10/4/1994	
	A 1 1 2	5360593		Bapatia	11/1/1994	
	A 1 1 3	5364633		Hill et al.	11/15/1994	
	A 1 1 4	5389377		Chagnon et al.	2/14/1995	
	A 1 1 5	5399363		Liversidge et al.	3/21/1995	
	A 1 1 6	5407683		Shively	4/18/1995	
	A 1 1 7	5439055		Card et al.	8/8/1995	
	A 1 1 8	5447710		Na et al.	9/5/1995	
	A 1 1 9	5470583		Na et al.	11/28/1995	
	A 1 2 0	5478860		Wheeler et al.	12/26/1995	
	A 1 2 1	5496818		Schaupp et al.	3/5/1996	
	A 1 2 2	5498420		Mentrup et al.	3/12/1996	
	A 1 2 3	5498421		Grinstaff et al.	3/12/1996	
	A 1 2 4	5510118		Bosch et al.	4/23/1996	
	A 1 2 5	5518730		Fuisz	5/21/1996	
	A 1 2 6	5527537		Dietl	6/18/1996	
	A 1 2 7	5529785		Dietl	6/25/1996	
	A 1 2 8	5536413		Bormann et al.	7/16/1996	
	A 1 2 9	5545628		Deboeck et al.	8/13/1996	
	A 1 3 0	5552160		Liversidge et al.	9/3/1996	
	A 1 3 1	5560931		Eickhoff et al.	10/1/1996	
	A 1 3 2	5569448		Wong et al.	10/29/1996	
	A 1 3 3	5569464		Endo et al.	10/29/1996	
	A 1 3 4	5571536		Eickhoff et al.	11/5/1996	
	A 1 3 5	5576016		Amselem et al.	11/19/1996	
	A 1 3 6	5578325		Domb et al.	11/26/1996	
MS	A 1 3 7	5589455		Woo	12/31/1996	
	A 1 3 8	5589508		Schlotzer et al.	12/31/1996	

Examiner Signature


Date Considered

5/9/05

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 13

Complete if Known

Application Number	09/281,430
Filing Date	March 30, 1999
First Named Inventor	INDU PARIKH
Group Art Unit	1615
Examiner Name	Todd Ware
Attorney Docket Number	402076 SKYEPHARMA

RECEIVED
APR 23 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
	A 1 3 9	5603951		Woo	2/18/1997	
	A 1 4 0	5607694		Marx	3/4/1997	
	A 1 4 1	5618522		Kaletta et al.	4/8/1997	
	A 1 4 2	5631019		Marx	5/20/1997	
	A 1 4 3	5631023		Kearney et al.	5/20/1997	
	A 1 4 4	5637625		Haynes	6/10/1997	
	A 1 4 5	5639474		Woo	6/17/1997	
	A 1 4 6	5648375		Abraham	7/15/1997	
	A 1 4 7	5651982		Marx	7/29/1997	
	A 1 4 8	5651991		Sugiyama et al.	7/29/1997	
	A 1 4 9	5656286		Miranda et al.	8/12/1997	
	A 1 5 0	5656289		Cho et al.	8/12/1997	
	A 1 5 1	5660837		Lundquist	8/26/1997	
	A 1 5 2	5660854		Haynes et al.	8/26/1997	
	A 1 5 3	5660858		Parikh et al.	8/26/1997	
	A 1 5 4	5662932		Amselem et al.	9/2/1997	
	A 1 5 5	5663198		Reul et al.	9/2/1997	
	A 1 5 6	5665700		Cho et al.	9/9/1997	
	A 1 5 7	5676928		Klaveness et al.	10/14/1997	
	A 1 5 8	5677341		Lyons	10/14/1997	
	A 1 5 9	5686102		Gross et al.	11/11/1997	
	A 1 6 0	5688528		Carlsson et al.	11/18/1997	
	A 1 6 1	5693337		Suzuki et al.	12/2/1997	
	A 1 6 2	5714520		Jones et al.	2/3/1998	
	A 1 6 3	5719197		Kanios et al.	2/17/1998	
	A 1 6 4	5731355		Jones et al.	3/24/1998	
	A 1 6 5	5731356		Jones et al.	3/24/1998	
	A 1 6 6	5733572		Unger et al.	3/31/1998	

Examiner Signature

Date Considered

5/9/05

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



RECEIVED

APR 23 2003

TECH CENTER 1600/290

Substitute for form 1449A/B/PTO				Compleat if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/281,430
				Filing Date	March 30, 1999
				First Named Inventor	INDU PARIKH
				Group Art Unit	1615
				Examiner Name	Fodd Ware Carlos Azpura
Sheet	6	of	13	Attorney Docket Number	402076 SKYEPHARMA


U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
AX	A 167	5750142		Friedman et al.	5/12/1998	
	A 168	5770222		Unger et al.	6/23/1998	
	A 169	5773026		Schlipalius	6/30/1998	
	A 170	5776491		Allen, Jr. et al.	7/7/1998	
	A 171	5776495		Duclos et al.	7/7/1998	
	A 172	5827520		Jones et al.	2/3/1998	
	A 173	5827536		Laruelle	10/7/1998	
	A 174	5827822		Floc'h et al.	10/27/1998	
	A 175	5834025		de Garavilla et al.	11/10/1998	
	A 176	5843465		Lundquist	12/1/1998	
	A 177	5851275		Amidon et al.	12/22/1998	
	A 178	5853755		Foldvari	12/29/1998	
	A 179	5858398		Cho	1/12/1999	
	A 180	5858410		Muller et al.	1/12/1999	
	A 181	5880148		Edgar et al.	3/9/1999	
	A 182	5885597		Botknecht et al.	3/23/1999	
	A 183	5908869		Jones et al.	6/1/1999	
	A 184	5912007		Pan et al.	6/15/1999	
	A 185	5912271		Brodin et al.	6/15/1999	
	A 186	5916596		Desai et al.	6/29/1999	
	A 187	5922355		Pariikh et al.	7/13/1999	
	A 188	5932243		Fricke et al.	8/3/1999	
	A 189	5958379		Regenold et al.	9/28/1999	
	A 190	5962536		Komer	10/5/1999	
	A 191	5972366		Haynes et al.	10/26/1999	
	A 192	5976577		Green et al.	11/2/1999	
	A 193	5994318		Gould-Fogerite et al.	11/30/1999	
	A 194	6013665		DeMichele et al.	1/11/2000	
	A 195	6017513		Betbeder et al.	1/25/2000	
	A 196	6019997		Scholz et al.	2/1/2000	
	A 197	6022547		Herb et al.	2/8/2000	
	A 198	6028108		George	2/22/2000	
	A 199	6031007		Brodin et al.	2/29/2000	
	A 200	6045829		Liversidge et al.	4/4/2000	
	A 201	6046163		Stuchlik et al.	4/4/2000	
	A 202	6057289		Mulye	5/2/2000	

Examiner Signature	<i>[Signature]</i>	Date Considered	5/4/03
--------------------	--------------------	-----------------	--------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

7

of

13

Complete if Known

Application Number 09/281,430
Filing Date March 30, 1999
First Named Inventor INDU PARIKH
Group Art Unit 1615
Examiner Name Todd Ware
Attorney Docket Number 402076 SKYEPHARM

RECEIVED
APR 23 2003

TECH CENTER 1600/2908

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
COA	A 203	6063762		Hong et al.	5/16/2000	
	A 204	6071927		Baker et al.	6/6/2000	
	A 205	6071928		Curtis et al.	6/6/2000	
	A 206	6075059		Reader	6/13/2000	
	A 207	6086376		Moussa et al.	7/11/2000	
	A 208	6096338		Lacy et al.	8/1/2000	
	A 209	6100302		Pejaver et al.	8/8/2000	
	A 210	6113921		Friedman et al.	9/5/2000	
	A 211	6120797		Meers et al.	9/19/2000	
	A 212	6121261		Glatt et al.	9/19/2000	
	A 213	6140373		May et al.	10/31/2000	
	A 214	6140374		May et al.	10/31/2000	
	A 215	6147122		Mirejovsky et al.	11/14/2000	
	A 216	6150423		Carpenter	11/21/2000	
	A 217	6153217		Jin et al.	11/28/2000	
	A 218	6160007		DeMichele et al.	12/12/2000	
	A 219	6177477		George et al.	1/23/2001	
	A 220	6180136		Larson et al.	1/30/2001	
	A 221	6190894		Thornfeldt et al.	2/20/2001	
	A 222	6197323		Georgieff	3/6/2001	
	A 223	6204257		Stella et al.	3/20/2001	
	A 224	6217886		Onyüksel et al.	4/17/2001	
	A 225	6221383		Miranda et al.	4/24/2001	
	A 226	6228399		Parikh et al.	8/8/2001	
	A 227	6232311		Rubniak et al.	5/15/2001	
	A 228	6242446		Glatt et al.	6/5/2001	
	A 229	6254853		Hendler et al.	7/3/2001	
	A 230	6261537		Klaveness et al.	7/17/2001	
	A 231	6264917		Klaveness et al.	7/24/2001	
	A 232	6264981		Zhang et al.	7/24/2001	
	A 233	6267985		Liversidge et al.	7/31/2001	

Examiner Signature

Date Considered

5/9/03

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



RECEIVED

APR 23 2003
TECH CENTER 1600/2000

Substitute for form 1449A/B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	09/281,430
			Filing Date	March 30, 1999
			First Named Inventor	INDU PARIKH
			Group Art Unit	1615
			Examiner Name	Todd Ware
Sheet 8 of 13	Attorney Docket Number		402076 SKYEPHARMA	


U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
SA	A 2 3 4	6267989		Liversidge et al.	7/31/2001	
	A 2 3 5	6270806		Liversidge et al.	8/7/2001	
	A 2 3 6	6274633		Franks et al.	8/14/2001	
	A 2 3 7	6281175		Lyons et al.	8/28/2001	
	A 2 3 8	6288040		Müller et al.	9/11/2001	
	A 2 3 9	6288127		Bienlarz et al.	9/11/2001	
	A 2 4 0	6294191		Meers et al.	9/25/2001	
	A 2 4 1	6294192		Patel et al.	9/25/2001	
	A 2 4 2	6297985		Kang	10/2/2001	
	A 2 4 3	6309623		Weers et al.	10/30/2001	
	A 2 4 4	6312715		Cantor et al.	11/6/2001	
	A 2 4 5	6326406		De Tommaso	12/4/2001	
	A 2 4 6	6328708		Georgieff	12/11/2001	
	A 2 4 7	6331289		Klaveness et al.	12/18/2001	
	A 2 4 8	6332138		Hull et al.	12/18/2001	
	A 2 4 9	6337092		Khan et al.	1/8/2002	
	A 2 5 0	6350480		Urnezis et al.	2/26/2002	
	A 2 5 1	6387409		Khan et al.	5/14/2002	
	A 2 5 2	6391336		Royer	5/21/2002	
	A 2 5 3	6391832		Lyons et al.	5/21/2002	
	A 2 5 4	6399087		Zhang et al.	6/4/2002	
	A 2 5 5	6410583		Labelle et al.	6/25/2002	
	A 2 5 6	6423338		Larson et al.	7/23/2002	
	A 2 5 7	RE32393		Wretlind et al.	4/7/1987	
	A 2 5 8	RE35338		Haynes	9/24/1996	
	A 2 5 9	2001/0007663		VON CORSWANT	7/12/2001	
	A 2 6 0	2001/0046474		Weers et al.	11/29/2001	

Examiner Signature	<i>[Signature]</i>	Date Considered	5/9/05
--------------------	--------------------	-----------------	--------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 13

Complete If Known	
Application Number	09/281,430
Filing Date	March 30, 1999
First Named Inventor	INDU PARIKH
Group Art Unit	1615
Examiner Name	Todd Ware
Attorney Docket Number	402076 SKYEPHARMA

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
	A 261		DE 2 513 797		Imperial Chemical Industries (see reference 4,056,635)	10/9/1975		X*
	A 262		DE 2 938 807		Green Cross Corp.	11/13/1980		X*
	A 263		DE 3 421 468		Dr. Rentschler Arzne. (see reference 4,880,634)	12/19/1985		X*
	A 264		DE 4 440 337		Rainer H. Müller (see reference 5,858,410)	5/15/1996		X*
	A 265		EP 0 036 277		Regents/ Univ. California	3/6/1981		
	A 262		EP 0 052 322		Gersonde, Klaus	5/26/1982		X*
	A 267		EP 0 153 926		Duncan H. Haynes	6/14/1984		
	A 268		EP 0 272 091		Vestar, Inc.	6/22/1988		
	A 269		EP 0 330 532		Fournier Industrie (see reference 4,895,726)	1/30/1989		X*
	A 270		EP 0 355 095		Liposome Comp., Inc.	8/4/1988		
	A 271		EP 0 391 369		Yissum Research Devel., Co.	4/4/1990		
	A 272		EP 0 418 153		Medgenix Group, S.A. (see reference 5,100,591)	3/20/1991		X*
	A 273		EP 0 456 670		B. Braun Melsungen AG	11/18/1993		X*
	A 274		EP 0 456 764		B. Braun Melsungen AG	9/1/1993		X*
	A 275		EP 0 499 299		Sterling Winthrop Inc.	8/19/1992		
	A 276		EP 0 570 829		Dr. Hans Dietl (see reference 5,527,537)	5/12/1993		X*
	A 277		EP 0 580 690		Sandoz Ltd.	2/2/1994		
	A 278		EP 0 589 843		Sandoz AG	9/21/1993		
	A 279		EP 0 601 618		Sterling Winthrop Inc.	10/30/1993		
	A 280		EP 0 605 497		Rainer Müller (see reference WO 93/05769)	3/20/1996		X*
	A 281		EP 0 724 877		Laboratoires Fournier S.C.A. (see reference 5,880,148)	8/7/1996		X*
	A 282		EP 0 757 911		CL Pharma (see reference 5,827,536)	2/12/1997		X*
	A 283		EP 0 770 381		L'OREAL (see reference 5,827,520)	5/2/1997		X*
	A 284		EP 0 602 700		Sterling Winthrop Inc.	12/1/1993		

Examiner Signature		Date Considered	5/4/05
--------------------	--	-----------------	--------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/281,430
Filing Date	March 30, 1999
First Named Inventor	INDU PARIK
Group Art Unit	1615
Examiner Name	Todd Ware
Attorney Docket Number	402076 SKYEPHARMA

RECEIVED
APR 23 2003
TECH CENTER 1600/2000

Sheet 10 of 13

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No ⁺
GFA	A 285		FR 2 617 047		Sanofiet Lab. Fournier	12-30-1988		X ⁺
	A 286		GB 1 527 638		Laboratories Fournier	3/20/1996		
	A 287		GB 2 046 094		Technicon Instruments Corp.	4-8-1980		
	A 288		GB 2 298 789		Zeneca Ltd.	3/17/1995		
	A 289		HU 211 580B		FGIS (see reference 5,168,847)	6/20/1995		X ⁺
	A 290		JP 1502590		A. Nattermann & Cie (see reference WO 88/04924)	11/12/1980		X ⁺
	A 291		JP 5221852A		LTT Kenkyusho	8/31/1993		X ⁺
	A 292		JP 55141407		A. Nattermann & Cie (see reference 4,309,421)	11/5/1980		X ⁺
	A 293		JP 56167616		Green Cross Corp. (see reference 4,340,594)	5/15/1980		X ⁺
	A 294		JP 60208910		A. Nattermann & Cie	11/5/1980		X ⁺
	A 295		JP 63233915		Green Cross Corp. (see reference 5,320,906)	10/21/1985		X ⁺
	A 296		JP 63502117		Liposome Technology, Inc. (see reference WO 87/04592)	9/3/1986		X ⁺
	A 297		WO 00/10531		RTP Pharma Inc.	3/2/2000		
	A 298		WO 00/24376		Abbott Laboratories	5/4/2000		
	A 299		WO 00/40219		Dexcel Ltd.	7/13/2000		
	A 300		WO 00/41682		LG Chemical Ltd.	7/20/2000		
	A 301		WO 00/54588		John C. Krusz	9/21/2000		
	A 302		WO 00/59471		Baxter International, Inc.	10/12/2000		
	A 303		WO 00/59472		Baxter International, Inc.	10/12/2000		
	A 304		WO 00/78301		Kuhnle Pharm. Co.	12/28/2000		
	A 305		WO 01/30372		Bask Aktiengesellschaft	5/3/2001		X ⁺
	A 306		WO 02/21517		Zeon Corp.	3/14/2002		
	A 307		WO 85/00011		University of Miami	1/3/1985		
	A 308		WO 87/04592		Liposome Technology, Inc.	8/13/1987		
	A 309		WO 88/04924		Liposome Tech., Inc.	7/14/1988		
	A 310		WO 91/16068		Duncan H. Haynes	10/31/1991		
	A 311		WO 9104011		Riker Laboratories, Inc.	4/4/1991		

Examiner Signature


[Handwritten Signature]

Date Considered

5/9/05

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete If Known

Application Number	09/281,430
Filing Date	March 30, 1999
First Named Inventor	INDU PARIKH
Group Art Unit	1615
Examiner Name	Todd Ware
Attorney Docket Number	402076 SKYEPHARMA

Sheet 11 of 13

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
	A 3 1 2		WO 92/18104		Vestar, Inc.	10/29/1992		
	A 3 1 3		WO 92/18105		Sandoz Ltd.	10/29/1992		
	A 3 1 4		WO 93/05768		Medac Gesellschaft	4/1/1993		
	A 3 1 5		WO 93/19736		Kabi Pharmacia	10/14/1993		
	A 3 1 6		WO 94/14415		Hemagen/PFC	7/7/1994		
	A 3 1 7		WO 94/20072		Pharmacia AB	9/15/1994		
	A 3 1 8		WO 94/26728		Chinoin Ltd.	11/24/1994		
	A 3 1 9		WO 96/01637		Astra Aktiebolag	6/21/1995		
	A 3 2 0		WO 96/19064		Xcellenet, Inc.	6/20/1996		
	A 3 2 1		WO 96/21439		Galephar P.R., Inc.	7/18/1996		
	A 3 2 2		WO 96/24332		Nanosystems, LLC	8/15/1996		
	A 3 2 3		WO 96/29064		Zeneca Limited	9/26/1996		
	A 3 2 4		WO 97/10814		Vesifact AG	3/27/1997		
	A 3 2 5		WO 97/14407		RTP Pharma Inc.	4/24/1997		
	A 3 2 6		WO 98/41239		Nycomed	9/24/1998		
	A 3 2 7		WO 98/53805		Saucy Limited	12-3-1998		
	A 3 2 8		WO 99/29300		RTP Pharma	6/17/1999		
	A 3 2 9		WO 99/29316		Cyclosporine Thera. Ltd.	6/17/1999		
	A 3 3 0		WO 99/39696		Gensia Sicor Inc.	8/12/1999		
	A 3 3 1		WO 99/49846		RTP Pharma	10/7/1999		
	A 3 3 2		WO 99/49848		RTP Pharma	10/7/1999		

Examiner
Signature

Date
Considered

5/9/03

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Complete if Known

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

12

of

13

Application Number

09/281,430

Filing Date

March 30, 1999

First Named Inventor

INDU PARIKH

Group Art Unit

1615

Examiner Name

Todd Ware

Attorney Docket Number

402076 SKYEPHARMA

OTHER - NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
AK	A 333	[LSP4]La Fuma Polymery 1998 43 nr 2, 104-108, "The role of water-soluble polymers at the solid/liquid etc."		
	A 334	"Derived Diameters and Distribution Statistics," from an unknown web-site, 6 pages		
	A 335	"Getting Started", Man 0106, Issue 1.0, (Jan. 1996), <i>Malvern Instruments Ltd.</i> , England, pp. 7.1-7.7		
	A 336	BANGHAM et al., "Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids", <i>J. Mol. Biol.</i> (1965) 13, pp. 238-252		
	A 337	BENZ et al., "Electrical Capacity of Black Lipid Films and of Lipid Bilayers Made from Monolayers", <i>Biochem. Biophys. Acta</i> , (1975) Vol. 394, pp. 323-334		
	A 338	BERGMANN, LUDWIG, <i>Der Ultraschall</i> , 5 Aufl., (1949), Stuttgart, S. 551-564, 672f		X
	A 339	BITTMAN, ROBERT, "Sterol-Polyene Antibiotic Complexation: Probe of Membrane Structure," <i>Lipids</i> , Vol. 13, No. 10, pp. 686-691 (1978).		
	A 340	BUCHMULLER et al., "Cryopel: Ein neues Verfahren zum Pelletieren und Frosten Biologischer Substrate," <i>Gas Aktuell</i> , 35, 1(1989), pp. 10-13		X
	A 341	CALVOR et al. <i>Pharm. Dev. Tech.</i> , 3(3), 297-205, 1998, "Production of Microparticles by High Pressure etc."		
	A 342	CHERNEY, L.S., "Tetracaine Hydroiodide: A Long Lasting Local Anesthetic Agent for the Relief of Postoperative Pain", <i>Anesth. Analg.</i> (1963) Vol. 42, No. 4, pp. 477-481		
	A 343	CHULIA et al., <i>Powder Technology and Pharmaceutical Processes</i> , (1994), pp. 66-67.		
	A 344	CUDD et al., "Liposomes Injected Intravenously into Mice Associate with Liver Mitochondria," <i>Biochem. Biophys. Acta</i> , (1984) Vol. 774, pp. 169-180		
	A 345	GENNARO et al., "Sustained-Release Drug Therapy," <i>Remington's Pharmaceutical Sciences</i> , 17 th Ed., (1985), p. 1645		
	A 346	GOODMAN and GILLMAN'S, "The Pharmacological Basis of Therapeutics," 7 th Ed., <i>MacMillan Publishing Co.</i> , New York (1985) Chap. 15, p. 312		
	A 347	GREGORIADIS, GREGORY, "The Carrier Potential of Liposomes in Biology and Medicine", <i>New Engl. J. Med.</i> , (1976) Vol. 295, No. 13, pp. 704-710		
	A 348	GUZMAN et al., 1088 <i>J. Pharm. Sci.</i> 82 (1993) No. 5 pp. 498-502 Formation and Characterization of Cyclosporine-Loaded Nanoparticles.		
	A 349	HAYNES et al., "Metal-Ligand Interactions in Organic Chemistry and Biochemistry", <i>B. Pullman and N. Goldblum (eds.)</i> , part 2, (1977), pp. 189-212		
	A 350	HAYNES et al., "Ultra-Long Duration Local Anesthesia Produced by Injection of Lecithin-coated Methoxyflurane Microdroplets", <i>Anesthesiology</i> (1985) Vol. 63, No. 5, pp. 490-499		

Examiner Signature		Date Considered	5/9/03
--------------------	--	-----------------	--------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	13	of	13
-------	----	----	----

C mplet if Known	
Application Number	09/281,430
Filing Date	March 30, 1999
First Named Inventor	INDU PARIKH
Group Art Unit	1615
Examiner Name	Todd Ware
Attorney Docket Number	402076 SKYEPHARMA

OTHER - NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	A 351	HERBERT A. LEIBERMAN and LEON LACHMAN, Eds., <i>Pharmaceutical Dosage Forms, Tablets, Vol. 1, (1980), p. 13</i>		
	A 352	HUANG et al., "Interaction of the N-terminus of Sterol Carrier Protein 2 with Membranes: Role of Membrane Curvature", <i>Biochem. J.</i> , (1999) Vol. 8, pp. 593-603		
	A 353	KIRKPATRICK et al., "Local Anesthetic Efficacy of Methoxyflurane Microdroplets in Man," <i>Anesthesiology</i> (1987) 67(3A): A254		
	A 354	LEHNINGER BIOCHEMISTRY, "The Molecular Basis of Cell Structure and Function", (1970) Chapter 10		
	A 355	LOURENCO et al., <i>Int. J. of Pharm.</i> 138 (1996), 1-12, "Steric stabilization of nanoparticles: size and surface properties".		
	A 356	LUCKHAM Pestic. Sci., 1989, 25, 25-34, "The Physical Stability of Suspension Concentrates with Particular etc."		
	A 357	MISHRA et al., "Scientifically Speaking: Novel Injectable Formulations of Water-Insoluble Drugs", <i>Controlled Release Newsletter</i> , Vol. 17, Issue 2, (June 2000), pp. 21-30		
	A 358	MIYAJIMA, KOICHIRO, "Role of Saccharides for the Freeze-Thawing and Freeze-Drying of Liposome", <i>Advanced Drug Delivery Review</i> , Vol. 24, (1997), pp. 151-159		
	A 359	MULLER et al., "Nanosuspensions for the I.V. Administration of Poorly Soluble Drugs-Stability During Sterilization and Long-Term Storage", Dept. of Pharmaceutics, Biopharmaceutics and Biotechnology, The Free University of Berlin, Kelchstraße 31, D-12169 Berlin, Germany		
	A 360	MULLER et al., <i>Emulsions and Nanosuspension</i> , Chap. 9 (1998) p. 163		
	A 361	NAPPER, "Polymeric Stabilizations of Colloidal Dispersions", (1983).		
	A 362	PACE et al., "Novel Injectable Formulations of Insoluble Drugs", <i>Pharmaceutical Technology</i> , Vol. 23, No. 3, (March 1999), pp. 116-134		
	A 363	ROMPP'S CHEMIE LEXIKON, 2 Aufl., Bd. 1, (1950), Stichwort, "Emulsion"		X
	A 364	ROSS et al., "Aqueous Solutions of Surface-Active Solutes", <i>Colloidal Systems and Interfaces</i> , © 1988, pp. 148-151		
	A 365	SANDE et al., "Antimicrobial Agents: Antifungal and Antiviral Agents", pp. 1219-1222		
	A 366	SIEKMANN et al. <i>Pharm. Pharmacol Lett</i> (1994) 3:225-228 "Melt-homogenized Solid Lipid Nanoparticles Stabilized by the Non-ionic Surfactant Tyloxapol".		
	A 367	Website http://userpage.fu-berlin.de/~kayser/nanosuspensionen.htm		
	A 368	WU et al., "Pharmacokinetics of Methoxyflurane After Its Intra-Dermal Injection as Lecithin-Coated Microdroplets", <i>Journal of Controlled Release</i> , (1989), Vol. 9, pp. 1-12		
	A 369	ZUIDAM et al. "Sterilization of Liposomes by Heat Treatment", <i>Pharmaceutical Research</i> , Vol. 10, No. 11, 1993 pg 1591-1596		

Examiner Signature		Date Considered	5/9/05
-----------------------	--	--------------------	--------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3)


Please type a plus sign (+) inside this box → +



RECEIVED
JUN 11 2003
TECH CENTER 1600/2800

Substitute for form 1449A/B/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: left;">Compleat if Known</th> </tr> <tr> <td style="width: 50%;">Application Number</td> <td>09/281,430</td> </tr> <tr> <td>Filing Date</td> <td>March 30, 1999</td> </tr> <tr> <td>First Named Inventor</td> <td>PARIKH</td> </tr> <tr> <td>Group Art Unit</td> <td>1615</td> </tr> <tr> <td>Examiner Name</td> <td><i>Twere Carlos Arpura</i></td> </tr> <tr> <td>Attorney Docket Number</td> <td>402076/SkyePharma</td> </tr> </table>		Compleat if Known		Application Number	09/281,430	Filing Date	March 30, 1999	First Named Inventor	PARIKH	Group Art Unit	1615	Examiner Name	<i>Twere Carlos Arpura</i>	Attorney Docket Number	402076/SkyePharma
Compleat if Known																	
Application Number	09/281,430																
Filing Date	March 30, 1999																
First Named Inventor	PARIKH																
Group Art Unit	1615																
Examiner Name	<i>Twere Carlos Arpura</i>																
Attorney Docket Number	402076/SkyePharma																
Sheet	1	of	5														

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
<i>[Signature]</i>	1	4,970,076		Horrobin	11/13/90	
	2	5,342,625		Hauer et al.	8/30/94	
	3	5,364,632		Benita et al.	11/15/94	
	4	5,437,055		Wheatley, III	7/25/95	
	5	5,603,951		Woo	2/18/97	
	6	5,639,724		Cavanak	6/17/97	
	7	5,652,212		Cavanak et al.	7/29/97	
	8	5,696,153		Ainsworth et al.	12/9/97	
	9	5,929,030		Hamied et al.	7/27/99	
	10	6,004,573		Rathi et al.	12/21/99	
	11	6,284,268		Mishra et al.	9/4/01	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
	12 ✓	EP	314 060		Warner-Lambert Co.	5/3/89		
	13 ✓	EP	539 319		Novartis AG	4/28/93		
	14 ✓	EP	589 843		Sandoz AG	3/30/94		
	15 ✓	EP	636 618		Marigen S.A.	2/1/95		X+
	16	EP	670 715		Gattefosse S.A.	9/13/95		X+
	17	EP	760 237		CIPLA Ltd.	3/5/97		
	18 ✓	UK	2 217 173		B A Whittle	10/25/89		
	19 ✓	WO	94/08603		Smith-Kline Beecham Corp.	4/28/94		
	20 ✓	WO	94/08605		Smith-Kline Beecham Corp.	4/28/94		
	21 ✓	WO	94/23733		DR. Rentschler Arzenemittel GMBH & Co.	10/27/94		X+
	22 ✓	WO	94/25068		Sherman	11/10/94		
	23 ✓	WO	95/11039		Hexal Pharma GMBH	4/27/95		X+
	24	WO	95/33490		Enzon, Inc.	12/14/95		
	25	WO	96/13273		Sandoz Ltd.	5/9/96		
	26	WO	96/35415		Sime et al.	11/14/96		
	27	WO	97/00080		Hexal AG	1/3/97		X+
	28	WO	97/02042		GS Development AB	1/23/97		
	29	WO	97/12626		Dietl	4/10/97		X+
	30	WO	97/19692		Sandoz-Patent-GMBH	6/5/97		
	31	WO	97/22358		Sherman	6/26/97		
	32	WO	97/25977		Novartis AG	7/24/97		
	33	WO	97/26003		Galena A S	7/24/97		
	34	WO	97/36610		Chong Kun Dang Corp.	10/9/97		

Examiner Signature <i>[Signature]</i>	Date Considered <i>5/9/05</i>
---------------------------------------	-------------------------------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → ☐



RECEIVED
JUN 11 2003
TECH CENTER 1000-2900

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	09/281,430	
			Filing Date	March 30, 1999	
			First Named Inventor	PARIKH	
			Group Art Unit	1615	
			Examiner Name	T. Ware Carlos A. 2	
Sheet	2	of	5	Attorney Docket Number	402076/SkyePharma


OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation		
			Yes	No**	
CA	35	Ardulno, M.J. et al., "Microbial Growth and Endotoxin Production in the Intravenous Anesthetic Propofol", Infection Control and Hospital Epidemiology, Vol. 12, No. 9, September 1991, pp. 535-539.			
	36	Attwood, David, "Microemulsions," Colloidal Drug Delivery Systems, © 1994, pp. 31-33.			
	37	Babl et al., "New Formulations of Propofol in an LCT/MCT Emulsion: Approach to Reduce Pain on Injection", Eur. Hosp. Pharmacy, January 1995, Vol. 1, No. 1, pp. 15-21.			
	38	Bennett et al., "Postoperative Infections Traced to Contamination of an Intravenous Anesthetic, Propofol", Natl. Ctr. for Infectious Diseases, Vol. 333, No. 3, (1999) pp. 2-9.			
	39	Cairns et al., "Tolerance of Mixed Lipid Emulsion in Neonates: Effect of Concentration", Archives of Disease in Childhood, (1996), Vol. 75, p. F113-F116.			
	40	Collins-Gold et al., "Parenteral Emulsions for Drug Delivery," Advanced Drug Delivery Reviews, (1990) Vol. 5, pp. 189-208.			
	41	Cox et al., "Influence of Different Fat Emulsion-Based Intravenous Formulations on the Pharmacokinetics and Pharmacodynamics of Propofol," Pharmaceutical Research, (1998) Vol. 15, No. 3, pp. 442-48.			
	42	Crowther et al., "Growth of Microorganisms in Propofol, Thiopental and a 1:1 Mixture of Propofol and Thiopental", Anesth. Analg., (1996), Vol. 82, pp. 475-478.			
	43	De Sommer et al., "A Comparative Study on the Effects of Propofol in Emulsion and Intralipid® on Fat Metabolism," Acta Anesthesiologica Belgica, (1990) Vol. 41, No. 2, pp. 133-138.			
	44	Dewandre et al., "A Comparison of the 2% and 1% Formulations of Propofol During Anaesthesia for Craniotomy," Anesthesia, (1994), Vol. 49, pp. 8-12.			
	45	"Diprivan 1% Injection," Physicians' Desk Reference, 1996, pp. 2833-39.			
	46	"Diprivan 1% Injection," Physicians' Desk Reference, 1999, pp. 3411-18.			
	47	Doenicke, A.W. et al., "Pharmacokinetics and Pharmacodynamics of Propofol in a New Solvent", Anesth. Analg., (1997), Vol. 85, pp. 1399-403.			
	48	Doenicke, A.W. et al., "Reducing Pain During Propofol Injection: The Role of the Solvent", Anesth. Analg., (1996), Vol. 82, pp. 472-4.			
	49	Eddleston et al., "The Effect on Serum Lipid Concentrations of a Prolonged Infusion of Propofol - Hypertriglyceridaemia Associated with Propofol Administration," Intensive Care Med., (1991), Vol. 17, pp. 424-426.			
	50	Ewart et al., "Forum: 2% Propofol for Sedation in the Intensive Care Unit, A Feasibility Study", Anaesthesia, February 1992, Vol. 47, No. 2, pp. 146-148.			
	51	Freeman, Andrew B., "A Technique for Reducing Pain Associated with Propofol Administration," Anesth. Analg., 1992 (1 page).			

Examiner Signature		Date Considered	5/9/03
-----------------------	--	--------------------	--------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).



+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → ☐



RECEIVED
 JUN 11 2003
 TECH CENTER 1600/2900

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
Sheet	3	of	5	Application Number	09/281,430
				Filing Date	March 30, 1999
				First Named Inventor	PARIKH
				Group Art Unit	1615
				Examiner Name	<u>I. Ware Carlos</u>
				Attorney Docket Number	402076/SkyePharma

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	52	Ghouri et al., "Effect of Flumazenil on Recovery after Midazolam and Propofol Sedation", Anesthesiology, (1994), Vol. 81, pp. 333-339.		
	53	Gottardis et al., Effect of Prolonged Sedation with Propofol on Serum Triglyceride and Cholesterol Concentrations, British J. Anaesthesia, (1989) Vol. 62, pp. 393-396.		
	54	King et al., "Lidocaine for the Prevention of Pain Due to Injection of Propofol", Anesth. Analg. (1992), Vol. 74, pp. 246-249.		
	55	Lindholm, Marianne, "Critically Ill Patients and Fat Emulsions," Minerva Anesthesiology, (1992), Vol. 58, No. 10, pp. 875-879.		
	56	Mangar et al., "Tourniquet at 50 mm Hg Followed by Intravenous Lidocaine Diminishes Hand Pain Associated with Propofol Injection", Anesth. Analg., (1992), Vol. 74, pp. 250-252.		
	57	Mirakhor et al., "Induction Characteristics of Propofol in Children: Comparison with Thiopentone", Anesthesia, (1998), Vol. 43, pp. 593-598.		
	58	Nichols, Ronald Lee, "Bacterial Contamination of an Anesthetic Agent," New Engl. J. Med., (1995), Vol. 333, No. 3, pp. 184-185.		
	59	Peereboom et al., "Successful Re-treatment with Taxol After Major Hypersensitivity Reactions", J. Clin. Oncology, Vol. 11 No. 5, 1993, pp. 885-890.		
	60	Sandstrom et al., "Structured Triglycerides Were Well Tolerated and Induced Increased Whole Body Fat Oxidation Compared With Long-Chain Triglycerides in Postoperative Patients", Journal of Parenteral and Enteral Nutrition, (1995), Vol. 19 No. 5, pp. 381-6.		
	61	Sharma et al., "Novel Taxol Formulations: Preparation and Taxation of Taxol-Containing Liposomes," Pharm. Res. Vol. 11 No. 6, 1994, pp.889-896.		
	62	Sklar, Grant E., "Propofol and Postoperative Infections," The Annals of Pharmacotherapy, (1997), Vol. 31, pp. 1521-3.		
	63	Smith et al., "Propofol: An Update on its Clinical Use," Anesthesiology, Oct. 1994, Vol. 81, No. 4, pp. 1005-1043.		
	64	Stark, et al., "A review of the safety and tolerance of propofol ('Diprivan')", Postgraduate Medical Journal, 1985, Vol. 61, Suppl. 3, pp. 152-156.		
	65	Stenz et al., "A new physiologically approached in vitro test for quick evaluation of the hemolytic activity of surfactants", Pharmazie, (1996), Vol. 51, No. 5, pp. 283-287.		
	66	Sosis et al., "Propofol, but not Thiopental, Supports the Growth of Candida albicans", Anesth. Anal., (1995), Vol. 81, pp. 132-134.		
	67	Tarr et al., "A New Parenteral Emulsion for the Administration of Taxol," Pharmaceutical Research, Vol. 2 No. 2, 1987, pp. 162-165.		

Examiner Signature		Date Considered	<u>5/9/05</u>
--------------------	--	-----------------	---------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

+

JUN 10 2003

TECH CENTER 1600 2300

JUN 11 2003

RECEIVED

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

5

Application Number

Complete if Known

09/281.430

Filing Date

March 30, 1999

First Named Inventor

PARIKH

Group Art Unit

1615

Examiner Name

~~T-Water~~

Attorney Docket Number

402076/SkyePharma

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
CA	68	Tessler et al., "Growth curves of Staphylococcus aureus, Candida, albicans, and Moraxella osloensis in propofol and other media", Can. J. Anaesth. (1992), Vol. 39 No. 5, pp. 509-511.		
	69	White et al., "Sedative Infusions During Local and Regional Anesthesia: A Comparison of Midazolam and Propofol", J. Clin. Anesth., Jan/Feb 1991, Vol. 3, pp. 32-39.		
	70	Sosis, et al., Growth of Staphylococcus aureus in Four Intravenous Anesthetics, Anesth Analg (1993) Vol. 77, pp. 766-768.		
	71	Groves, et al., "The self-emulsifying action of mixed surfactants in oil", Acta Pharm. Suecica, Vol. 13, (1976), pp. 361-372.		
	72	Sharma, et al., "Novel Taxol® Formulation: Polyvinylpyrrolidone Nanoparticle-Encapsulated Taxol® for Drug Delivery in Cancer Therapy", Oncology Research, Vol. 8, Nos. 7/8, pp. 281-286, (1996).		
	73	Wheeler, et al., "Polyethylene Glycol Modified Phospholipids Stabilize Emulsions Prepared from Triacylglycerol", J. of Pharmaceutical Sciences, Vol. 83, No. 11, pp. 1558-1564, (Nov. 1994).		
	74	Lundberg, B., "Preparation of Drug-Carrier Emulsions Stabilized with Phosphatidylcholine-Surfactant Mixtures", J. of Pharmaceutical Sciences, Vol. 83, No. 1, pp. 72-75, (1994).		
	75	Sjöström, et al., "A Method for the Preparation of Submicron...and Surfactant Concentration", J. of Pharmaceutical Sciences, Vol. 82, No. 6, pp. 579-583, (June 1993).		
	76	Benita, et al., "Submicron Emulsions as Colloidal Drug...Physicochemical Characterization", J. of Pharmaceutical Sciences, Vol. 82, No. 11, pp. 1069-1079, (Nov. 1993).		
	77	Lundberg, B., "A Submicron Lipid Emulsion Coated with Amphipathic Polyethylene Glycol for Parenteral Administration of Paclitaxel (Taxol)", J. Pharm. Pharmacol., Vol. 49, pp. 16-21, (1997).		
	78	Adams, et al., "Taxol: A History of Pharmaceutical Development and Current Pharmaceutical Concerns", J. of the Natl. Cancer Inst. Monographs, No. 15, pp. 141-147, (1993).		
	79	Terwogt, et al., "Alternative formulations of paclitaxel", Cancer Treatment Reviews, Vol 23, pp. 87-95, (1997).		
	80	Groves et al., "Rheological characterization of self-emulsifying oil/surfactant systems", Acta Pharm. Suecica, Vol. 13, pp. 353-360, (1976).		
MA	81	Eugster, et al., "Marigenol® Concentrates comprising Taxol and/or Taxan esters as active substances", Panminerva Med., Vol. 38, pp. 234-242, (1996).		


**Examiner
Signature**

Date
Considered

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

+



RECEIVED
JUN 11 2003
TECH CENTER 1600/2800

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

5

of

5

Complete if Known

09/281,430

Filing Date

March 30, 1999

First Named Inventor

PARIKH

Group Art Unit

1615

Examiner Name

F. Ware

Attorney Docket Number

402076/SkyePharma

OTHER - NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

* An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).